Pancreatic Cancer
Conditions
Keywords
insulinoma, cancer of pancreas, neoplasms, pancreas, alpha-cell tumor, glucagonoma, beta-cell tumor, somatostatinoma
Brief summary
Cancer results from multiple mutations which cause cells to grow uncontrolled. It therefore may be necessary to inhibit several oncogenic targets to affect cancer cell growth. Studies have shown that panobinostat (LH589) causes a wide range of effect on endothelial cells that lead to inhibition of tumor angiogenesis (a fundamental step in the transition of tumors from a dormant state to a malignant one). Bortezomib triggers cell death in pancreatic cancer cells but the mechanism is not well defined but has been determined to be cytostatic. Combining these two drugs may work together in the treatment of pancreatic cancer.
Interventions
DRUGBortezomib
1.3 mg/m\^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
DRUGPanobinostat
20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
Sponsors
Novartis Pharmaceuticals
Millennium Pharmaceuticals, Inc.
Masonic Cancer Center, University of Minnesota
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological diagnosis of locally advanced or metastatic pancreatic cancer (except neuroendocrine tumors, but including ampullary cancer) with progression after standard first line therapy that included gemcitabine (single agent or combination) * Measurable disease on computated tomography (CT) scan per Response Evaluation Criteria in Solid Tumors (RECIST) criteria * At least 28 days from previous systemic therapy, including investigational agents and 1st dose of study treatment and recovered from any acute toxic effects of that treatment before study enrollment. * Has Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 - Ability to provide written consent * Must meet hematology and biochemistry laboratory criteria within 14 days of study enrollment: * Neutrophil count \>1500/mm\^3 * Platelet count \>100,000/mm\^L * Hemoglobin \> or = 9 g/dL * Aspartate aminotransferase (AST/SGOT) or Alanine transaminase (ALT/SGPT) \< or = 2.5 times upper limit of normal (ULN)or ≤ 5.0 x ULN if the transaminase elevation is due to disease involvement * Serum bilirubin \< or = 1.5 x ULN * Serum creatinine \< or = 1.5 x ULN or 24-hour creatinine clearance ≥ 50 ml/min * Total serum calcium (corrected for serum albumin) or ionized calcium ≥ lower limit of normal (LLN) * Serum phosphorus \> or = LLN * Serum potassium \> or = LLN * Serum sodium ≥ LLN * Serum magnesium ≥ LLN * Serum albumin ≥ LLN or 3g/dl * Patients with any elevated Alkaline Phosphatase due to bone metastasis can be enrolled * Baseline multi gated acquisition scan (MUGA) or echocardiogram (ECHO) must demonstration left ventricular ejection fraction (LVEF) \> or = 50% * Normal thyroid function within normal limits. Note: Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism. * Women of childbearing potential (WOCBP) must have a negative pregnancy tests within 7 days of study treatment administration and willing to use 2 methods of contraception
Exclusion criteria
* \> 1 prior systemic treatment regimen for pancreatic cancer * Prior histone deacetylase (HDAC), deacetylase (DAC), heat shock protein 90 (HSP90) inhibitors or valproic acid for treatment of cancer * Anyone needing valproic acid for any medical condition during the study or 5 days prior to panobinostat treatment * Impaired cardiac function * Complete left bundle branch block or use of a permanent cardiac pacemaker, congenital long QT syndrome, history or presence of ventricular tachyarrhythmias, clinically significant resting bradycardia (\<50 beats per minute), QTcF \> 450 msec on screening ECG, or right bundle branch block + left anterior hemiblock (bifascicular block) * Presence of atrial fibrillation (ventricular heart rate \>100 bpm) * Previous history angina pectoris or acute myocardial infarction (MI) within 6 months of study enrollment * Congestive heart failure (New York Heart Association functional classification III-IV) or baseline MUGA/Echo shows LVEF \< 50% * Uncontrolled hypertension defined as hypertensive blood pressure of SBP \> 140 or DBP \> 90, despite antihypertensive medications * History of deep vein thrombosis (DVT), pulmonary emboli or other blood clotting abnormality within 3 months of study enrollment * Ongoing need for anti-coagulation therapy except daily low dose aspirin (≤ 100 mg/day) or low molecular weight heparin * Concomitant use of drugs with risk of causing torsades de pointes * Anyone with unresolved diarrhea \> or = grade 2 at time of enrollment * Impairment of gastrointestinal function or disease that may significantly alter the absorption of panobinostat * Grade 2 or greater peripheral neuropathy within 14 days of enrollment * Serious concomitant medical or psychiatric disorders (e.g., active infection, uncontrolled diabetes) * Patients who have received chemotherapy, any investigational agent or undergone major surgery \< 4 weeks prior to starting study drug * Male patients whose sexual partners are WOCBP and not using double method of contraception during the study and 3 months following. * Known positivity for human immunodeficiency virus (HIV) or hepatitis C * Hypersensitivity to bortezomib, boron or mannitol History of another primary malignancy within 5 years other than curatively treated CIS of the cervix, or basal or squamous cell carcinoma of the skin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival | Up to 1 Year | Median number of months before disease progressed in patient on gemcitabine when treated with the combination of panobinostat and bortezomib. Progression free survival is measured from randomization until the subject has documented disease progression by an objective measure. Subjects must be alive with no more than 20% increase in tumor size to qualify for progression free survival. Changes in tumor size are defined by RECIST criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants by Tumor Response | Up to 1 Year | Number of patients whose tumor has responded to study therapy is determined using Response Evaluation Criteria In Solid Tumors. Progressive Disease (PD) is assessed if the sum of the diameters has increased by ≥ 20% and ≥ 5 mm from nadir (including baseline if it is the smallest sum). Objective response is measured by tumor reduction as defined in the RECIST criteria. Tumor shrinkage must be at least 30% to qualify as an objective response. |
| Duration of Response | Up to 1 Year | Duration of response is calculated as (Date of First Disease Progression or Death as a Result of any Cause whichever Comes First - Date of First Objective Status Assessment of Confirmed Complete or Partial Response as defined by RECIST criteria). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Pancreatic Cancer Patients Pancreatic cancer patients who received treatment with bortezomib (1.3 mg/m\^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period) and panobinostat (20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period) after progressing on gemcitabine. | 7 |
| Total | 7 |
Baseline characteristics
| Characteristic | Pancreatic Cancer Patients |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 3 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants |
| Age, Continuous | 58 years STANDARD_DEVIATION 13 |
| Region of Enrollment United States | 7 participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 7 / 7 |
| serious Total, serious adverse events | 4 / 7 |
Outcome results
Primary
Progression-Free Survival
Median number of months before disease progressed in patient on gemcitabine when treated with the combination of panobinostat and bortezomib. Progression free survival is measured from randomization until the subject has documented disease progression by an objective measure. Subjects must be alive with no more than 20% increase in tumor size to qualify for progression free survival. Changes in tumor size are defined by RECIST criteria.
Time frame: Up to 1 Year
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Pancreatic Cancer Patients | Progression-Free Survival | 2.1 Months |
Secondary
Duration of Response
Duration of response is calculated as (Date of First Disease Progression or Death as a Result of any Cause whichever Comes First - Date of First Objective Status Assessment of Confirmed Complete or Partial Response as defined by RECIST criteria).
Time frame: Up to 1 Year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pancreatic Cancer Patients | Duration of Response | 0 Weeks |
Secondary
Number of Participants by Tumor Response
Number of patients whose tumor has responded to study therapy is determined using Response Evaluation Criteria In Solid Tumors. Progressive Disease (PD) is assessed if the sum of the diameters has increased by ≥ 20% and ≥ 5 mm from nadir (including baseline if it is the smallest sum). Objective response is measured by tumor reduction as defined in the RECIST criteria. Tumor shrinkage must be at least 30% to qualify as an objective response.
Time frame: Up to 1 Year
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Pancreatic Cancer Patients | Number of Participants by Tumor Response | Progressive Disease | 5 Participants |
| Pancreatic Cancer Patients | Number of Participants by Tumor Response | No data available | 2 Participants |
| Pancreatic Cancer Patients | Number of Participants by Tumor Response | Objective Response | 0 Participants |